Capstone Copper Corp
OTC:CSCCF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Capstone Copper Corp
OTC:CSCCF
|
CA |
|
Valbiotis SA
F:8JD
|
FR |
|
Telix Pharmaceuticals Ltd
F:T3X
|
AU |
|
Kuala Lumpur Kepong Bhd
OTC:KLKBF
|
MY |
|
KULR Technology Group Inc
F:7FA0
|
US |
|
C
|
Chorus Ltd
OTC:CHRUF
|
NZ |
|
Sassy Gold Corp
OTC:SSYRF
|
CA |
|
S
|
SK Securities No.12 Special Purpose Acquisition Co
KOSDAQ:473000
|
KR |
|
ATON Green Storage SpA
F:6E6
|
IT |
|
B
|
Bossard Holding AG
F:0B7
|
CH |
|
Carriage Services Inc
NYSE:CSV
|
US |
|
P
|
Poujoulat SA
LSE:0AB0
|
FR |
|
XTM Inc
OTC:XTMIF
|
CA |
|
W
|
Westwater Resources Inc
F:UCCP
|
US |
|
K
|
KULR Technology Group Inc
XMUN:7FA0
|
US |
|
A
|
Abercrombie & Fitch Co
DUS:AFT
|
US |
|
Four Corners Property Trust Inc
F:4Z1
|
US |
|
Lisi SA
F:LI3
|
FR |
|
D
|
Dave and Buster's Entertainment, Inc
SWB:9DB
|
US |
Earnings Calls
Last Earnings Call
Record results: Capstone posted record quarterly EBITDA of $354 million and record adjusted net income of $97.6 million, helped by stronger production and higher copper prices.
Operational strength: Mantoverde delivered record throughput and record low cash costs, Mantos Blancos stayed on plan, and Cozamin remained a steady performer, while Pinto Valley is still being repaired and optimized.
Guidance unchanged: Management reaffirmed 2026 production, cost and CapEx guidance, saying second-half output should be stronger, especially at Mantoverde.
Growth pipeline: Mantoverde Optimized remains on schedule and on budget, Santo Domingo is still targeted for a Q4 sanctioning decision, and Mantos Blancos has moved ahead with a new EIA permit application.
Cost defense: The company cut exposure to expensive sulfuric acid and diesel, shifting more tonnage to higher-margin sulfides and temporarily reducing Mantoverde heap leach activity.
Balance sheet: Net debt fell to $675 million and leverage improved to 0.5x, with more deleveraging expected from cash flow.
Portfolio review: Management said it continues to evaluate Cozamin as part of portfolio rationalization, but stressed the asset remains highly cash generative.